Mobile

A randomized, double-blind, placebo controlled, multicenter, 3-period crossover study to compare the effect of indacaterol (150μg o.d.) on inspiratory capacity to placebo in patients with moderate COP...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-013686-26

A randomized, double-blind, placebo controlled, multicenter, 3-period crossover study to compare the effect of indacaterol (150μg o.d.) on inspiratory capacity to placebo in patients with moderate COPD, using open label tiotropium (18μg o.d.) as active control

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate the superiority of indacaterol (150µg o.d.) compared to placebo with respect to Peak Inspiratory Capacity after 21 days of treatment.

Critère d'inclusion

  • moderate chonic obstructive pulmonary disease (COPD)

Liens